Literature DB >> 32103492

GILZ in sepsis: "Poor is the pupil who does not surpass his master".

Jolien Vandewalle1,2, Claude Libert1,2.   

Abstract

With the legendary saying of Leonardo da Vinci in the title, we suggest that Glucocorticoid Induced Leucine Zipper (GILZ) may have more promising effects against polymicrobial sepsis, than glucocorticoids (GC). Indeed, the use of GCs in sepsis remains a matter of debate. The rationale for their use in sepsis is to modulate the exaggerated inflammatory response while maintaining innate immunity. However, GC resistance and side-effects limit their therapeutic value in sepsis. Hence, there is a growing interest in understanding the mechanisms by which GCs modulate immune responses upon infection. In this issue of the European Journal of Immunology, Ellouze et al. provide data demonstrating that deregulated expression of GILZ, a GC-induced protein, in monocytes/macrophages (M/M) recovered from septic shock patients may contribute to the pathogenesis. Furthermore, the authors demonstrate that GILZ overexpression in M/M improves outcome in septic animals by limiting systemic inflammation while increasing bacterial clearance. Overall, these data provide evidence that GCs may modulate immune responses via GILZ and that GILZ is a valuable alternative for GC therapy in sepsis.
© 2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  GILZ; glucocorticoids; immunomodulation; phagocytosis; sepsis

Year:  2020        PMID: 32103492     DOI: 10.1002/eji.202048582

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  2 in total

Review 1.  Glucocorticoid-Induced Leucine Zipper: A Promising Marker for Monitoring and Treating Sepsis.

Authors:  Ya-Jun He; Ji-Qian Xu; Miao-Miao Sun; Xiang-Zhi Fang; Zhe-Kang Peng; Shang-Wen Pan; Ting Zhou; Ya-Xin Wang; You Shang
Journal:  Front Immunol       Date:  2020-12-16       Impact factor: 7.561

Review 2.  Glucocorticoids in Sepsis: To Be or Not to Be.

Authors:  Jolien Vandewalle; Claude Libert
Journal:  Front Immunol       Date:  2020-07-21       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.